Sluchay total'nogo limfomatoidnogo polipoza zheludochno-kishechnogo trakta pri limfome zony mantii
- Autores: Alekseeva Y.A1, Vabishchevich R.I1
-
Afiliações:
- Edição: Nº 17 (2013)
- Páginas: 75-79
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282544
- ID: 282544
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Total lymphomatoid polyposis of the gastrointestinal tract against the background of mantle zone lymphoma is a rare form of the disease with a poor prognosis. The article presents the description of the clinical case. In 45 year-old man with symptoms of gastrointestinal bleeding, multiple polyps throughout the gastrointestinal tract were revealed using endoscopic examination. The diagnosis of mantle zone lymphoma was verified by immunohistochemistry. On the basis of this case, problems of prediction, complications and treatment of this form of the disease are discussed.
Texto integral
Bibliografia
- Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111,2385-87(2008).
- Khouri IF, Romaguera J, Kantarjian H, et al., Champlin Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16( 12):3803.
- Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005;16: 618-24.
- Williams ME, Dreyling M, Winter J, et al. Management of Mantle Cell Lymphoma: Key Challenges and Next Steps Clinical Lymphoma Myeloma and Leukemia 2010;10(5): 336-46.
- Pott C , Hoster E, et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL NetworkASH53, 2011.
- Chan JK. Gastrointestinal lymphomas:an overview with emphasis on new findings and diagnostic problems. Semin Diagn Pathol 1996; 13:260-96.
- Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12(4):361.
- Zhang L, Qian Z, Cai Z, et al.Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep;84(9):553-59.
- Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622.
- Goy SH, Bernstein BS, Kahl B, et al. PINNACLE Study Group Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol 2006;24(18):7512.
- JW Friedberg, JM Vose et al. The combination of bendamustine, bortesomibe, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Blood 2011;117:2807-12.
- Lancet Oncol. 2009. Опубликовано в электронной версии журнала 25 мая 2009 года Авастин (бевацизумаб) существенно повышает риск перфорации органов желудочно- кишечного тракта.
- Sandborn WJ, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98: 1309-14.
- Sherpo MT, et al. Gastrointestinal Mantle Cell Lymphoma incedented finding on routine CT scan following pneumotorax. J Advances Internal Med 2013;02(02)24-6.
Arquivos suplementares
